Proven reduction of pain and opioid use*

EXPAREL vs bupivacaine HCI in TKA1

78%

FEWER OPIOIDS


overall opioid consumption

P<0.005

Significantly better

PAIN CONTROL


cumulative pain scores

P<0.04

1 out of 10 patients who received EXPAREL was opioid-free

10% with
exparel

(n=70)

vs

(P<0.01)

0% WITH
BUPIVACAINE
HCI

(n=69)

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Results from a phase 4, double-blind, randomized, controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA study. Primary end points: area under the curve (AUC) of visual analog scale pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness, and muscle spasms.

EXPAREL vs placebo in hemorrhoidectomy2,3

Significantly lower

OPIOID USE*


45% lower overall
opioid consumption

P=0.0006

Significantly better

PAIN CONTROL


30% lower cumulative
pain scores

P<0.0001

3 out of 10 patients who received EXPAREL were opioid-free2

28% with
exparel

(n=95)

vs

(P<0.0008)

10% WITH
PLACEBO

(n=94)

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.

Results from a phase 3, multicenter, randomized double-blind, placebo-controlled trial that evaluated the efficacy of 166 mg (20 mL) of EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary end point: cumulative pain score reflected in AUC of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg) of morphine administered intramuscularly) was available to all patients.

EXPAREL vs placebo in ISBP nerve block for total shoulder arthroplasty and rotator cuff repair study4

78%

FEWER OPIOIDS


overall opioid consumption

P<0.0001

Significantly better

PAIN CONTROL


cumulative pain scores

P<0.0001

Significantly more patients were opioid-free with EXPAREL

23% AT 24 HOURS

P<0.0001

AND

13% AT 48 HOURS

P=0.008

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Rescue opioids for pain were available upon patient request.

Results from a phase 3, multicenter, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary end points: pain intensity through 48 hours postsurgery, as measured by AUC of VAS pain intensity scores, and total postsurgical opioid consumption.

EXPAREL TAP block vs bupivacaine TAP block in C-section study

52%

FEWER OPIOIDS at 72 hours


overall opioid consumption

P<0.001

Comparable

PAIN CONTROL

through 72 hours


overall opioid consumption

P=0.0117

Results from a prospective, 13-site, multicenter, randomized clinical trial, EXPAREL significantly improved postsurgical recovery when used in a TAP block after C-section. Primary end point: EXPAREL reduced opioid consumption by 52%, compared with standard bupivacaine, over 72 hours and maintained a significant opioid-minimizing effect over 2 weeks.5

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

The reduction in opioid consumption continued for two weeks postpartum.

TKA, total knee arthroplasty; ISBP, interscalene brachial plexus; TAP, transversus abdominis plane.